| |
Unfavorable vs. favorable
|
OS
|
RFS
|
|---|
|
HR
|
95% CI
|
P-value
|
HR
|
95% CI
|
P-value
|
|---|
|
Univariate analysis
|
|
Sex
|
Female vs. male
|
1.075
|
0.502–2.305
|
0.8517
|
1.269
|
0.586–2.750
|
0.5455
|
|
Age
|
≥70 vs. < 70 years
|
2.369
|
1.152–4.870
|
0.0190*
|
1.020
|
0.510–1.960
|
0.9543
|
|
Histology
|
Adenocarcinoma vs. others
|
1.171
|
0.602–2.277
|
0.6419
|
1.265
|
0.635–2.520
|
0.5037
|
|
Tumor size
|
> 30 vs. ≤30 mm
|
0.892
|
0.427–1.865
|
0.7622
|
1.066
|
0.495–2.296
|
0.8710
|
|
CEA
|
≥5.0 vs. < 5.0 ng/mL
|
1.235
|
0.634–2.405
|
0.5348
|
2.901
|
1.374–6.127
|
0.0052*
|
|
Primary tumor SUVmax
|
High vs. low
|
2.284
|
1.159–4.502
|
0.0171*
|
2.312
|
1.155–4.630
|
0.0180*
|
|
Multivariate analysis
|
|
Sex
|
Female vs. male
|
1.315
|
0.556–3.276
|
0.5564
|
1.018
|
0.430–2.413
|
0.9669
|
|
Age
|
≥70 vs. < 70 years
|
2.751
|
1.300–5.822
|
0.0081*
|
1.130
|
0.545–2.343
|
0.7419
|
|
Histology
|
Adenocarcinoma vs. others
|
1.970
|
0.754–5.149
|
0.1668
|
1.353
|
0.575–3.181
|
0.4884
|
|
Tumor size
|
> 30 vs. ≤30 mm
|
1.989
|
0.603–6.565
|
0.2589
|
0.523
|
0.186–1.475
|
0.2205
|
|
CEA
|
≥5.0 vs. < 5.0 ng/mL
|
1.039
|
0.504–2.143
|
0.9170
|
2.376
|
1.056–5.348
|
0.0366*
|
|
Primary tumor SUVmax
|
High vs. low
|
5.121
|
1.759–14.910
|
0.0027*
|
2.789
|
1.042–7.458
|
0.0410*
|
- HR Hazard ratio, CI Confidence interval. *P < 0.05
